MedTrace Logo

Tranexamic Acid for the Prevention of Blood Loss in High Risk Delivered Women

NCT04201951 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 196

Last updated 2020-12-24

No results posted yet for this study

Summary

Postpartum hemorrhage and its complications are very well known causes for maternal mortality .Uterine atony is the most common cause for postpartum hemorrhage

Conditions

  • Postpartum Hemorrhage
  • High Risk Pregnancy
  • Tranexamic Acid
  • Third-Stage Postpartum Hemorrhage, With Delivery

Interventions

DRUG

Tranexamic acid injection

Participant in group A will receive 2 ampules of 5 milliliters (mL) Tranexamic acid applied to 20 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus

OTHER

Glucose water 5%

Group B will receive 30 mL of 5% glucose water slowly intravenously immediately after the delivery of the fetus

Sponsors & Collaborators

  • Hawler Medical University

    lead OTHER

Principal Investigators

  • Shahla K. Alalaf, professor · Hawler Medical University

  • Sazgar A. Rashid, FIBOG · Ministery of Health

  • Chro S. Hassan, MBChB · Kurdistan Board for Medical Speciality

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2020-10-10
Completion
2020-10-10

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04201951 on ClinicalTrials.gov